La cadena de opciones muestra datos clave de las opciones de acciones de Alzamend Neuro a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Alzamend Neuro..

Alzamend Neuro (NASDAQ:ALZN) Bolsa, Cadena de Opciones

ALZAMEND NEURO INC

Alzamend Neuro

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

SILO

Descubre las últimas transacciones de insiders en penny stocks como ALZN, GANX, AZTR y SILO. ¡Aprovecha esta información privilegiada ahora!

Compras de insiders de penny stocks: ALZN, GANX, AZTR, SILO

Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) narrows FY2025 sales outlook from $4.296 billion-$4.597 billion to $4.382 billion-$4.511 billion vs $4.442 billion estimate.

Guidance

GNRC

Generac Hldgs Narrows FY2025 Sales Guidance from $4.296B-$4.597B to $4.382B-$4.511B vs $4.442B Est

CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) reported quarterly earnings of $2.10 per share which met the analyst consensus estimate. This is a 9.95 percent increase over earnings of $1.91 per share from the same period last year. The company reported quarterly sales of $4.090 billion which beat the analyst consensus estimate of $4.010 billion by 2.00 percent. This is a 11.38 percent increase over sales of $3.672 billion the same period last year.

Earnings

Earnings Beats

TSX:GIB

TSX:GIB.A

CGI Q3 Adj. EPS $2.10, Inline, Sales $4.090B Beat $4.010B Estimate

UTHR

United Therapeutics Q2 2025 EPS $6.41 Misses $7.14 Estimate, Sales $798.600M Miss $805.482M Estimate

CGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIB#NYSE">GIB</a>) reported quarterly earnings of $1.52 per share which missed the analyst consensus estimate of $2.10 by 27.55 percent. This is a 8.57 percent increase over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $2.955 billion which missed the analyst consensus estimate of $4.019 billion by 26.48 percent. This is a 10.10 percent increase over sales of $2.684 billion the same period last year.

Earnings Misses

CGI Q3 Adj. EPS $1.52 Misses $2.10 Estimate, Sales $2.955B Miss $4.019B Estimate

Strategic Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.43 by 7.47 percent. This is a 15.79 percent increase over earnings of $1.33 per share from the same period last year. The company reported quarterly sales of $321.471 million which missed the analyst consensus estimate of $322.867 million by 0.43 percent. This is a 2.95 percent increase over sales of $312.266 million the same period last year.

STRA

Strategic Education Q2 Adj. EPS $1.54 Beats $1.43 Estimate, Sales $321.471M Miss $322.867M Estimate

Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $0.98 by 23.6 percent. This is a 4.72 percent decrease over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $2.615 billion which beat the analyst consensus estimate of $2.518 billion by 3.82 percent. This is a 26.07 percent increase over sales of $2.074 billion the same period last year.

Hershey Q2 Adj. EPS $1.21 Beats $0.98 Estimate, Sales $2.615B Beat $2.518B Estimate

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has the highest percentage of retail investor ownership in the company among other trillion-dollar companies.
Check out the current price of <a href="https://benzinga.com/quote/tsla">TSLA stock here</a>.
What Happened: Tesla's retail investors hold 42% of the company's shares, a number that exceeds other trillion-dollar companies, influencer Sawyer Merritt shared in a post on X on Tuesday, citing Bloomberg data from <a href="https://www.barrons.com/livecoverage/tesla-earnings-stock-price-elon-musk/card/tesla-and-the-trillion-dollar-club-ZM9iFbgMtAE1n5AnyQbl">a</a> Barron's report.
Other companies include tech giants like Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Alphabet Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Retail investors own 42% of Tesla shares— a higher percentage than retail investors hold in other trillion dollar companies. <a href="https://t.co/6Lb3h3IxGR">pic.twitter.com/6Lb3h3IxGR</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1950206601995891075?ref_src=twsrc%5Etfw">July 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Interestingly, Tesla CEO Elon Musk had shared his desire to have over 25% control in Tesla in a post on social media platform X last year.&nbsp;
"I am uncomfortable growing Tesla to be a leader in AI &amp; robotics without having ~25% voting control. Enough to be influential, but not so much that I can't be overturned," Musk had said in the post.
He added that he would explore other opportunities and "build products outside of Tesla" if he couldn't have 25% control. "You don't seem to understand that Tesla is not one startup, but a dozen," Musk said in the post.
He also shared that firms like Fidelity owned similar shares to Musk, but "why don't they show up for work?" he asked in the post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am uncomfortable growing Tesla to be a leader in AI &amp; robotics without having ~25% voting control. Enough to be influential, but not so much that I can't be overturned. Unless that is the case, I would prefer to build products outside of Tesla. You don't seem to understand…
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1746999488252703098?ref_src=twsrc%5Etfw">January 15, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The data comes as Musk's control over Tesla was brought into question, as the billionaire was criticized for his <a href="https://www.benzinga.com/markets/tech/25/07/46268694/elon-musks-america-party-plans-conflict-with-his-full-time-responsibilities-as-tesla-ceo-says-former-doge-advisor">involvement in politics</a> by experts like former DOGE advisor James Fishback.
Gerber Kawasaki's co-founder Ross Gerber had also criticized Tesla's board and the company, saying that Musk had <a href="https://www.benzinga.com/markets/tech/25/07/46337215/tesla-is-basically-hijacked-by-elon-musk-says-ross-gerber-calling-it-completely-ridiculous-america-party-is-the-worst-news-for-tsla">"hijacked" the company</a> and that his political activities would harm the EV giant.
Wedbush Securities analyst Dan Ives had also criticized Musk and laid out a plan for Tesla following the America Party row. However, he was asked <a href="https://www.benzinga.com/markets/tech/25/07/46335539/elon-musk-asked-dan-ives-to-shut-up-and-the-tesla-bull-says-thats-cool-heres-why">to "shut up"</a> by Musk on social media.
However, Musk&#8217;s stake in Tesla, as well as his pay package, has been subject to scrutiny as some members of the board disagree with the billionaire's <a href="https://www.benzinga.com/markets/tech/25/07/46359669/teslas-annual-shareholder-meeting-set-for-november-6th-dan-ives-says-elon-musks-pay-package-in-the-spotlight">$56 billion pay package</a>.&nbsp;
Tesla, on the other hand, posted lackluster results in its Q2 earnings call. However, the company has recently signed major <a href="https://www.benzinga.com/markets/tech/25/07/46682096/elon-musk-said-he-would-walk-the-line-personally-following-16-5-billion-samsung-deal-is-this-a-return-to-wartime-ceo-mode">multi-billion-dollar</a> deals with Korean companies like Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) and LG Energy Solutions over AI chips and <a href="https://www.benzinga.com/markets/tech/25/07/46711313/elon-musks-tesla-lg-energy-solutions-sign-4-3-billion-battery-deal-report">energy storage options</a>, respectively.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="198" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30060538/TSLA-JUL-30-2025-2-1024x198.jpg" alt="" class="wp-image-1006771" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30060538/TSLA-JUL-30-2025-2-1024x198.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30060538/TSLA-JUL-30-2025-2-300x58.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30060538/TSLA-JUL-30-2025-2-768x149.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30060538/TSLA-JUL-30-2025-2-1536x298.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/30060538/TSLA-JUL-30-2025-2.jpg 1559w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla scores well on Momentum and Quality, while offering satisfactory Growth, but poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46713345/gary-black-says-a-smaller-tesla-pickup-truck-would-significantly-expand-earnings-potential-calls-the-cybertruck-a-disaster">Gary Black Says A Smaller Tesla Pickup Truck Would Significantly Expand Earnings Potential, Calls The Cybertruck A &#8216;Disaster&#8217;</a></li>
</ul>

Tech

AAPL

GOOG

GOOGL

MSFT

NVDA

SSNLF

TSLA

Elon Musk Wants 25% Voting Control In Tesla: Data Shows EV Giant Has Highest Retail Ownership Among Trillion Dollar Companies

Grant funds will also launch the development of Ohio's first statewide prescription drug repository

Cardinal Health Expands Equity Rx To Boost Prescription Access In Four States And Launch Ohio's First Statewide Drug Repository

2025 guidance
Today, the Company raises 2025 full-year guidance, reflective of healthy capital investment trends, operational execution and changes in tariff rates, as follows:
<ul>
<li>Organic revenue growth&#x2A; of approximately 3% year-over-year; this compares to previous Organic revenue growth&#x2A; guidance of 2% to 3%</li>
<li>Adjusted EBIT margin&#x2A; of 15.2% to 15.4%, reflecting a decline of 110 bps to 90 bps versus 2024 Adjusted EBIT margin&#x2A; of 16.3%; this compares to previous Adjusted EBIT margin&#x2A; guidance of 14.2% to 14.4%</li>
<li>Adjusted effective tax rate (ETR)&#x2A; in the range of 20% to 21%; this compares to previous Adjusted ETR&#x2A; guidance of 21% to 22%</li>
<li>Adjusted EPS&#x2A; in the range of $4.43 to $4.63, which includes approximately $0.45 of tariff impact versus 2024 Adjusted EPS&#x2A; of $4.49; this compares to previous Adjusted EPS&#x2A; guidance in the range of $3.90 to $4.10</li>
<li>Free cash flow&#x2A; of at least $1.4 billion; this compares to previous Free cash flow&#x2A; guidance of at least $1.2 billion</li>
</ul>
Tariff assumptions for updated guidance: Bilateral U.S. and China tariffs introduced this year continue and will rise on August 12, 2025 (to a rate of 54% for U.S. tariffs imposed on goods imported from China to the U.S. and to 34% for Chinese tariffs on goods exported from the U.S. to China); U.S. reciprocal rate on EU and Japan products at 15% effective August 1, 2025; tariffs increase for goods imported from Mexico (to 30%) and from Canada (to 35%) on August 1, 2025 and USMCA exemptions for eligible imports continue; U.S. reciprocal tariffs on all other impacted geographies return to pre-pause levels on August 1, 2025, including other increases formally communicated by letter (&gt;10%); excludes potential Section 232 tariff impact.

GEHC

GE HealthCare Techs Raises FY2025 Adj EPS Guidance From $3.90-$4.10 to $4.43-$4.63 vs $4.07 Est

As President Donald Trump touts major trade deals with the European Union, Japan, Vietnam and Indonesia, a vast majority of humanity is yet to sign on with the new paradigm of global trade with the United States.
What Happened: On Sunday, U.S. Commerce Secretary Howard Lutnick warned that August 1 will be the &#8220;hard deadline&#8221; for countries that haven&#8217;t yet signed a trade deal with the U.S. to start <a href="https://www.benzinga.com/markets/economic-data/25/07/46512424/howard-lutnick-says-trumps-august-1-tariff-hard-deadline-is-final-smaller-nations-face-10-base-rate">paying the tariffs</a>. 
While there have been several new trade agreements over the past couple of weeks, it is worth noting that these countries account for just over 12% of the world&#8217;s population. Several larger nations, which make up a bigger chunk of U.S. foreign trade, are yet to sign a deal. 
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46678323/trumps-trade-deals-have-a-hidden-cost-says-economist-peter-schiff-less-demand-for-treasuries-higher-prices-for-consumers">Trump&#8217;s Trade Deals Have A Hidden Cost, Says Economist Peter Schiff: Less Demand For Treasuries, Higher Prices For Consumers</a>
Here are a few of the largest U.S. trading partners that are yet to sign, and are now set to face the August 1 deadline on the tariffs.
<h2 class="wp-block-heading">1. China</h2>
Treasury Secretary Scott Bessent held another <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46677080/trump-xi-meeting-on-horizon-as-us-china-hold-marathon-5-hour-trade-talks-in-stockholm">round of talks</a> with the nation&#8217;s third-largest trading partner in Stockholm early this week. 
In 2024, the total goods trade between the U.S. and China was valued at $582 billion, according <a href="https://ustr.gov/countries-regions/china-mongolia-taiwan/peoples-republic-china">to</a> the United States Trade Representative, making this one of the most monumental deals that is currently in the works.
Over a month ago, President Donald Trump had posted on Truth Social <a href="https://www.benzinga.com/news/politics/25/06/45764844/trump-says-he-likes-xi-jinping-of-china-but-calls-him-very-tough-and-extremely-hard-to-make-a-deal-with">that he likes</a> President Xi Jinping of China, &#8220;always have, and always will,&#8221; he said, adding that &#8220;he is very tough, and extremely hard to make a deal with!&#8221;
<h2 class="wp-block-heading">2. Mexico &amp; Canada</h2>
Two of the largest trading partners of the United States, talks have continued with both nations in recent weeks, with no conclusion in sight.
Last week, Trump said, &#8220;We haven't really had a lot of luck with Canada,&#8221; and suggested the country may simply <a href="https://www.benzinga.com/news/politics/25/07/46647776/us-may-ditch-trade-negotiations-with-canada-trump-says-havent-really-had-a-lot-of-luck">be forced to pay</a> a 35% tariff.
Canadian Prime Minister&nbsp;Mark Carney had said previously that his country &#8220;will not accept a bad deal&#8221; or be rushed into an agreement.
With Mexico, Trump has cited fentanyl trafficking as the basis for a threatened 30% tariff. Earlier this year, a 25% tariff was already imposed. Mexico remains the largest source <a href="https://ustr.gov/countries-regions/americas/mexico">of</a> U.S. imports, totaling nearly $506 billion in 2024, while U.S. exports reached $334 billion.
<h2 class="wp-block-heading">3. India</h2>
A deal with India also appears distant. When asked on Tuesday whether an agreement had been finalized, Trump replied, &#8220;No, it's not,&#8221; according to a report by Reuters. 
India was already hit with a 26% tariff in April, and Trump is now threatening a 25% rate. U.S.-India trade totaled around $130 billion last year, according <a href="https://ustr.gov/countries-regions/south-central-asia/india">to</a> the U.S. Trade Representative data.
<h2 class="wp-block-heading">4. Taiwan</h2>
After being hit with a 32% tariff in April, Taiwan continues to reel from uncertainty, as officials in Taipei reportedly fear they could be excluded from any deal if Trump prioritizes China, according <a href="https://thehill.com/homenews/administration/5426189-mexico-canada-trump-tariffs/">to</a> a report by The Hill.
A source reportedly told The Hill that the country is &#8220;actively contemplating the prospect of a new go-it-alone era, where Taipei can no longer count on support from the White House.&#8221; In 2024, U.S. imports from Taiwan totaled $116 billion, and exports at $42 billion, according <a href="https://ustr.gov/countries-regions/china/taiwan">to</a> the USTR.
<h2 class="wp-block-heading">5. Brazil</h2>
Brazil has been threatened with a 50% tariff, with Trump <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46334793/trump-sends-lula-a-letter-imposing-50-tariffs-calls-bolsonaro-trial-a-witch-hunt-brazils-president-hits-back-will-not-accept-any-form-of-tutelage">linking the mov</a>e to the prosecution of former President Jair Bolsonaro, which he referred to as &#8220;a Witch Hunt that should end IMMEDIATELY.&#8221;
Brazil was already hit with a 10% tariff in April. U.S. imports from Brazil totaled over $42 billion in 2024, while exports <a href="https://ustr.gov/countries-regions/americas/brazil">to</a> Brazil reached nearly $50 billion.
<h2 class="wp-block-heading">6. Switzerland</h2>
Swiss President Karin Keller-Sutter said in July that both sides were nearing an agreement to secure a trade deal soon, after having been hit with a 31% tariff in April. 
The nation ranks among the Top 20 U.S. trading partners, with imports from Switzerland totaling $63 billion <a href="https://ustr.gov/countries-regions/europe-middle-east/europe/switzerland">in</a> 2024 and exports at $25 billion.
<h2 class="wp-block-heading">7. Thailand</h2>
Thailand is back at the negotiating table following a ceasefire with Cambodia. Trump said he instructed his trade team to restart talks. Thailand was hit with a 36% tariff in April, and its acting prime minister said Trump promised a "very good" outcome during discussions.
The Southeast Asian country ranks high on the list of U.S. trading partners, with the total goods trade between the nations <a href="https://ustr.gov/countries-regions/southeast-asia-pacific/thailand">at</a> $81 billion in 2024.
Why It Matters: Trump has just <a href="https://www.benzinga.com/news/politics/25/07/46714946/trump-warns-india-of-25-tariffs-as-trade-talks-stall-ahead-of-august-1-deadline">warned India of 25% tariffs</a> as trade talks stall ahead of the August 1 deadline, without any finalized agreements in place. 
Sen.&nbsp;Lindsey Graham&nbsp;(R-S.C.) had previously said previously hinted at a different strategy for the BRICS nations, which includes India. This would involve a <a href="https://www.benzinga.com/news/politics/25/07/46541364/trump-plans-100-tariffs-on-india-brazil-china-for-backing-russian-oil-and-fueling-putins-war-machine-says-lindsey-graham">100% tariff on China, India and Brazil</a> for buying Russian oil. 
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/07/46686877/drug-prices-to-get-more-expensive-under-trumps-eu-trade-deal-as-pharma-faces-billions-in-added-costs-report">Drug Prices To Get &#8216;More Expensive&#8217; Under Trump&#8217;s EU Trade Deal As Pharma Faces Billions In Added Costs: Report</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Trump Is Yet To Sign A Trade Deal With Over 85% Of Humanity — Here Are The Major Countries That Are Yet To Sign

GE HealthCare Techs Q2 2025 Adj. EPS $1.06 Beats $0.92 Estimate, Sales $5.007B Beat $4.962B Estimate

OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) affirms FY2025 GAAP EPS guidance from $2.21-$2.33 to $2.21-$2.33 vs $2.27 analyst estimate..

OGE Energy Affirms FY2025 GAAP EPS Guidance of $2.21-$2.33 vs $2.27 Est

OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) reported quarterly earnings of $0.53 per share which missed the analyst consensus estimate of $0.56 by 5.36 percent. This is a 3.92 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $741.600 million which beat the analyst consensus estimate of $719.970 million by 3.00 percent. This is a 11.92 percent increase over sales of $662.600 million the same period last year.

OGE Energy Q2 EPS $0.53 Misses $0.56 Estimate, Sales $741.600M Beat $719.970M Estimate

Company Raises Full-Year 2025 Guidance
&nbsp;
•The Company expects full-year 2025 reported revenue growth of approximately 9 percent, including 100 basis points related to acquisitions, and organic revenue growth of approximately 8 percent versus full-year 2024.
•The Company expects GAAP continuing EPS for full-year 2025 of approximately $13.30, including $0.25 for non-GAAP adjustments. The Company expects adjusted continuing EPS for full-year 2025 of approximately $13.05.

Trane Technologies Raises FY2025 GAAP EPS Guidance from $12.95-$13.15 to $13.30 vs $13.03 Est

Trane Technologies Raises FY2025 Adj EPS Guidance from $12.70-$12.90 to $13.05 vs $12.93 Est; Raises FY2025 Sales Guidance from $21.326B-$21.524B to $21.623B vs $21.533B Est

WIIM

United Microelectronics shares are trading lower following worse-than-expected Q2 financial results.

Teradyne shares are trading higher following better-than-expected Q2 EPS and sales.

FTAI

FTAI Aviation shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

Vertiv shares are trading higher after reporting better-than-expected Q2 EPS and sales and raising FY25 EPS and sales guidance above estimates.

QRVO

Qorvo shares are trading higher after the company reported better-than-expected Q1 financial results and issued strong guidance.

Health Care

Press Releases

General

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor's Drink Expansion – More Stocks Inside

Financing

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Comments

Alzamend Neuro

Alzamend Neuro (ALZN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL